Home LiteratureArticle Details
PMID: 6251750 Published · ppublish English Journal Article

Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.

Antimicrobial agents and chemotherapy ·Vol. 18 ·No. 1 ·1980-07-00 ·Pages 88-93

Fuchs PC, Barry AL, Thornsberry C, Jones RN, Gavan TL, Gerlach EH, Sommers HM

Abstract

Tested against 9,412 recent clinical isolates, cefotaxime exhibited 8 to 64 times greater activity against the Enterobacteriaceae than did cephalothin and two to four times greater activity against Pseudomonas aeruginosa, but only one-half to one-eighth the activity of cephalothin against staphylococci. Using 420 different clinical isolates, but with comparable minimal inhibitory concentration (MIC) distributions, disk diffusion-MIC regression analyses were performed, using 5- and 30-micrograms cefotaxime disks. Cefotaxime MIC susceptible and resistant breakpoints of less than or equal to 8 and greater than 32 micrograms/ml are tentatively proposed. Based on the MIC breakpoints, the data showed the best discrimination among the three susceptibility categories (susceptible, indeterminate, and resistant) when the 30-micrograms cefotaxime disk was used. The zone diameter breakpoints as determined by the error rate-bounded method and regression analysis were greater than or equal to 23 mm for susceptible, 15 to 22 mm for indeterminate, and less than or equal to 14 mm for resistant.

MeSH Terms
Bacteria/drug effects Cefotaxime Cephalosporins/metabolism,pharmacology Enterobacteriaceae/drug effects Humans Microbial Sensitivity Tests/methods Pseudomonas/drug effects Regression Analysis
Chemicals
Cephalosporins Cefotaxime
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Fuchs P C
Barry A L
Thornsberry C
Jones R N
Gavan T L
Gerlach E H
Sommers H M
References (11)
11 references, click to expand
  1. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.
    J Infect Dis. 1974 Dec;130(6):588-94 PMID: 4372272
  2. BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins.
    J Antibiot (Tokyo). 1977 Jul;30(7):583-92 PMID: 893227
  3. Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro.
    J Antimicrob Chemother. 1978 Sep;4(5):437-44 PMID: 308505
  4. Activity of HR 756 against Haemophilus influenzae, Bacteroides fragilis and Gram-negative rods.
    J Antimicrob Chemother. 1978 Sep;4(5):445-50 PMID: 308506
  5. beta-lactamase stability of HR 756, a novel cephalosporin, compared to that of cefuroxime and cefoxitin.
    Antimicrob Agents Chemother. 1978 Sep;14(3):322-6 PMID: 101128
  6. In vitro activity of HR 756, a new cephalosporin compound.
    J Antibiot (Tokyo). 1978 Nov;31(11):1170-4 PMID: 102631
  7. HR 756, the syn isomer of a new methoxyimino cephalosporin with unusual antibacterial activity.
    Antimicrob Agents Chemother. 1978 Nov;14(5):749-54 PMID: 31836
  8. HR 756, a highly active cephalosporin: comparison with cefazolin and carbenicillin.
    Antimicrob Agents Chemother. 1978 Dec;14(6):807-11 PMID: 253572
  9. In vitro of cefotaxime against cephalothin-resistant clinical isolates.
    Antimicrob Agents Chemother. 1979 Jul;16(1):109-11 PMID: 475369
  10. Human pharmacology of cefotaxime (HR 756), a new cephalosporin.
    Antimicrob Agents Chemother. 1979 Aug;16(2):127-33 PMID: 485125
  11. Diffusion disk susceptibility testing with cefotaxime.
    Antimicrob Agents Chemother. 1979 Aug;16(2):164-6 PMID: 114106
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1980-07-00
Pages
88-93
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC283944
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]